title: Practicing safe cell culture: applied process designs for minimizing virus contamination risk.
abstract: CONFERENCE PROCEEDING Proceedings of the PDA/FDA Adventitious Viruses in Biologics: Detection and Mitigation Strategies Workshop in Bethesda, MD, USA; December 1-3, 2010 Guest Editors: Arifa Khan (Bethesda, MD), Patricia Hughes (Bethesda, MD) and Michael Wiebe (San Francisco, CA) Genentech responded to a virus contamination in its biologics manufacturing facility by developing and implementing a series of barriers specifically designed to prevent recurrence of this significant and impactful event. The barriers included steps to inactivate or remove potential virus particles from the many raw materials used in cell culture processing. Additionally, analytical testing barriers provided protection of the downstream processing areas should a culture contamination occur, and robust virus clearance capability provided further assurance of virus safety should a low level contamination go undetected. This conference proceeding will review Genentech's approach, and lessons learned, in minimizing virus contamination risk in cell culture processes through multiple layers of targeted barriers designed to deliver biologics products with high success rates.
authors.affiliation: Late Stage Cell Culture, Pharmaceutical Technical Development, Genentech, Inc. (a member of the Roche Group).
authors.forename: Robert D
authors.initials: RD
authors.lastname: Kiss
mesh_terms: D001688:Biological Products; D018929:Cell Culture Techniques; D004340:Drug Contamination / Q000517:prevention & control; D005506:Food Contamination; D006801:Humans; D012306:Risk; D012449:Safety; D014780:Viruses
chemical_list: D001688:Biological Products